Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma-Reference-Cited by-同舟云学术

Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma

Published:2017-12-23 Issue:1 Volume:30 Page:13-22
ISSN:0953-8178
Container-title:International Immunology
language:en
Short-container-title:

Author:

Takeuchi Yoshiko¹²,Tanemura Atsushi³,Tada Yasuko¹,Katayama Ichiro³,Kumanogoh Atsushi²,Nishikawa Hiroyoshi¹⁴

Affiliation:

1. Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan

2. Department of Respiratory Medicine and Clinical Immunology

3. Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan

4. Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Japan Agency for Medical Research and Development

National Cancer Center Research and Development Fund

Naito Foundation

Publisher

Oxford University Press (OUP)

Subject

Immunology,General Medicine,Immunology and Allergy

Link

http://academic.oup.com/intimm/article-pdf/30/1/13/24729983/dxx073.pdf

Reference62 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med,2010

2. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med,2012

3. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J. Clin. Oncol,2014

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N. Engl. J. Med,2015

5. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N. Engl. J. Med,2013

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy;Cancers;2024-06-30

2. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration;Cancer Immunology, Immunotherapy;2024-05-15

3. Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment;Translational Oncology;2024-05

4. Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment;Cancer Immunology, Immunotherapy;2024-01

5. Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma;Immuno-Oncology and Technology;2023-12